Abstract：Objective To assess the diagnostic value of the propranolol-exercise provocative test for growth hormone deficiency (GHD) in children. Methods This study included 120 children who received both the insulin provocative test and the propranolol-exercise provocative test due to short stature between January 2009 and March 2013. Growth hormone (GH) levels in venous blood were measured before and after the provocative test. Peak GH <10 ng/mL was defined as negative stimulation, while peak GH ≥10 ng/mL was defined as positive stimulation. The children whose peak GH levels were <10 ng/ mL after both tests were diagnosed with GHD. Results Twenty-nine (24.2%) of the 120 children with short stature were diagnosed with GHD. The positive rate in the insulin provocative test was 48.3%, versus 65.8% in the propranolol-exercise provocative test. The overall coincidence rate and positive coincidence rate of the two tests were 62.5% and 79.3%, respectively. The peak GH after the propranolol-exercise provocative test was significantly higher than that after the insulin provocative test (P<0.01). Peak GH occurred mostly at 30-60 minutes after the insulin provocative test, while that occurred mostly at 120 minutes after the propranolol-exercise provocative test. No adverse effects were observed in the propranolol-exercise provocative test. Conclusions Coincidence rates in stimulating the secretion of GH are high between the propranolol-exercise provocative test and the insulin provocative test. Compared with the insulin provocative test, the propranolol-exercise provocative test is more likely to stimulate the secretion of GH. GHD can be clinically diagnosed by the insulin provocative test combined with the propranolol-exercise provocative test.
ZHENG Fang-Yuan,WANG Xue-Mei,WANG Xin-Li. Diagnostic value of the propranolol-exercise provocative test for growth hormone deficiency in children[J]. CJCP, 2015, 17(2): 180-184.
Carrascosa A, Audi L, Fernandez-Cancio M, et al. Growth hormone secretory status evaluated by growth hormone peak after two pharmacological growth hormone release stimuli did not significantly influence the two-year catch-up growth induced by growth hormone therapy in 318 prepubertal short children with idiopathic growth retardation[J]. Horm Res Paediatr, 2011, 75(2): 106-114.
[2]
Bohdanowicz-Pawlak A, Szymczak J, Bladowska J, et al. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report[J]. Med Sci Monit, 2006, 12(2): R75-R80.
[3]
颜纯, 王慕逖. 小儿内分泌学[M]. 北京: 人民卫生出版社, 2006: 91-132.
[4]
Munoz-Hoyos A, Hubber E, Escames G, et al. Effect of propranolol plus exercise on melatonin and growth hormone levels in children with growth delay.[J]. J Pineal Res, 2001, 30(2): 75-81.
Galluzzi F, Quaranta MR, Salti R, et al. Are IGF-I and IGF-BP3 useful for diagnosing growth hormone deficiency in children of short stature?[J]. J Pediatr Endocrinol Metab, 2010, 23(12): 1273-1279.
[8]
Lee HS, Hwang JS. Influence of body mass index on growth hormone responses to classic provocative tests in children with short stature[J]. Neuroendocrinology, 2011, 93(4): 259-264.
van Vught AJ, Nieuwenhuizen AG, Gerver WJ, et al. Pharmacological and physiological growth hormone stimulation tests to predict successful GH therapy in children[J]. J Pediatr Endocrinol Metab, 2009, 22(8): 679-694.
[11]
Tanaka T. Global situation of growth hormone treatment in growth hormone- deficient children[J]. Horm Res, 1999, 51 (Suppl 3): 75-80.
[12]
Friend K, Iranmanesh A, Login IS, et al. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release[J]. Eur J Endocrinol, 1997, 137(4): 377-386.
Ghigo E, Bellone J, Aimaretti G, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children[J]. J Clin Endocrinol Metab,1996, 81(9): 3323-3327.
